Single Dose, Open Label, Uncontrolled, Safety Trial of Intravenous Administration of Idarucizumab to Paediatric Patients Enrolled From Ongoing Phase IIb/III Clinical Trials With Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism.
Phase of Trial: Phase III
Latest Information Update: 05 Jan 2018
At a glance
- Drugs Idarucizumab (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 21 Dec 2017 Planned End Date changed from 30 Nov 2018 to 7 Nov 2018.
- 21 Dec 2017 Planned primary completion date changed from 30 Nov 2018 to 7 Nov 2018.
- 14 Nov 2017 Planned number of patients changed from 10 to 5.